Pharmaceutical compositions comprising nilotinib
Disclosed herein is a composition comprising: an amorphous solid dispersion (ASD) comprising nilotinib and at least one polymeric stabilizing and matrix-forming component; and at least one solid organic acid in admixture with the ASD, and uses thereof in the treatment of proliferative disorder.
1. A composition comprising:
(a) a particulate amorphous solid dispersion (ASD) comprising nilotinib free base and copovidone; and
(b) asborbic acid in admixture with the particular ASD;
wherein the nilotinib is present in an amount of from abuot 20% w/w to about 30% w/w of the particulate ASD; and
wherein the ascorbic acid is present in an amount of from about 0.5 to about 5 times the amount of nilotinib (weight to weight).
2. The composition of claim 1 , wherein the ascorbic acid is present in an amount of from about 1 to about 3 times the amount of nilotinib (weight to weight).
3. The composition of claim 1 , wherein the ascorbic acid is present in an amount of from about 1 to about 1.5 times the amount of nilotinib (weight to weight).
4. The composition of claim 1 , wherein the ascorbic acid is present in an amount of about 1.3-1.6 times the amount of nilotinib (weight to weight).
5. The composition of claim 1 , wherein the particulate ASD has one or more of (1) a bulk density of about 0.42 g/mL, (2) a tapped density of about 0.63 g/mL, and (3) a particle size distribution of about 72% w/w (<125 μm), about 20.8% w/w (125-250 μm), about 5.7% w/w (250-425 μm), about 0.7% w/w (425-600 μm), and about 0.8% w/w (>600 μm).
6. The composition of claim 1 , wherein the composition has about 0.1 to about 100 ppm of Nilotinib Impurity A.
7. A pharmaceutical composition comprising the composition of claim 6 and one or more pharmaceutically acceptable excipients.
8. The pharmaceutical composition of claim 7 , wherein the ascorbic acid is present in an amount of about 1.3-1.6 times the amount of nilotinib (weight to weight).
9. The pharmaceutical composition of claim 7 , wherein the ascorbic acid is present in an amount of about 1.5 times the amount of nilotinib (weight to weight).
10. The pharmaceutical composition of claim 7 , wherein the particulate ASD has one or more of (1) a bulk density of about 0.42 g/mL, (2) a tapped density of about 0.63 g/mL, and (3) a particle size distribution of about 72% w/w (<125 μm), about 20.8% w/w (125-250 μm), about 5.7% w/w (250-425 μm), about 0.7% w/w (425-600 μm), and about 0.8% w/w (>600 μm).
11. A method for the treatment of a condition in a patient, which comprises: administering to the patient in need thereof the pharmaceutical composition of claim 7 comprising a therapeutically effective amount of nilotinib;
wherein the condition is selected from the group consisting of:
(1) for an adult patient with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase; and
(2) for adult patients with chronic phase (CP) and accelerated phase (AP) Ph+CML resistant to or intolerant to prior therapy that included imatinib.
12. The pharmaceutical composition of claim 7 , wherein the one or more pharmaceutically acceptable excipients comprises a poly(methacrylic acid, ethyl acrylate).
13. The composition of claim 1 , wherein the particulate ASD consists of nilotinib free base and copovidone.
14. The composition of claim 1 , wherein the nilotinib is present in an amount of about 25% w/w of the particulate ASD.
15. An immediate release pharmaceutical composition comprising the composition of claim 14 and one or more pharmaceutically acceptable excipients comprising a poly(methacrylic acid, ethyl acrylate).
16. A method for the treatment of a condition in a patient, which comprises: administering to the patient in need thereof the pharmaceutical composition of claim 15 comprising a therapeutically effective amount of nilotinib;
wherein the condition is selected from the group consisting of:
(1) for an adult patient with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) in chronic phase; and
(2) for adult patients with chronic phase (CP) and accelerated phase (AP) Ph+CML resistant to or intolerant to prior therapy that included imatinib.
17. The composition of claim 1 , wherein the ascorbic acid is present in an abount of about 1 to about 1.5 times the amount of nilotinib (weight to weight) and an amount of Nilotinib Impurity A is less than about 6 ppm.
18. An immediate release pharmaceutical composition comprising the composition of claim 14 and one or more pharmaceutically acceptable excipients; wherein an amount of Nilotinib Impurity A is less than about 6 ppm.
19. A method for the treatment of a condition in a patient, which comprises: administering to the patient in need thereof the pharmaceutical composition of claim 18 comprising a therapeutically effective amount of nilotinib;
wherein the condition is selected from the group consisting of:
(1) for an adult patient with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia Ph+CML) in chronic phase; and
(2) for adult patients with chronic phase (CP) and accelerated phase (AP) Ph+CML resistant to or intolerant to prior therapy that included imatinib.
20. The composition of claim 1 having about 1.4 ppm nilotinib impurity A after 5 weeks when stored at 40° C. and 75% humidity.